vimarsana.com
Home
Live Updates
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation : comparemela.com
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
– Newly published data highlights additional efficacy endpoints from trial –
– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years...
Related Keywords
Massachusetts ,
United States ,
Switzerland ,
Boston ,
China ,
Rome ,
Lazio ,
Italy ,
Japan ,
Georgee Batchelor ,
,
Ironwood Pharmaceuticals Nasdaq ,
Jerome Foundation ,
University Of Miami Health System ,
University Of Miami ,
Ironwood Pharmaceuticals Inc ,
National Population Projection Tables ,
Drug Administration ,
Division Of Pediatric Gastroenterology ,
Linkedin ,
Ironwood Pharmaceuticals ,
Astrazeneca ,
Nasdaq ,
Lancet Gastroenterology ,
Miguel Saps ,
Pediatric Gastroenterology ,
Endowed Chair ,
Miami Health ,
Common Adverse Reactions ,
Prescribing Information ,
Boxed Warning ,
Childhood Functional Gastrointestinal Disorders ,
Functional Gastrointestinal Disorders ,
Population Projection Tables ,
Functional Defecation Disorders ,
Systemic Review ,
Markets ,
comparemela.com © 2020. All Rights Reserved.